CR20150134A - Arry-520 para uso en el tratamiento del cáncer en un paciente con aag baja - Google Patents

Arry-520 para uso en el tratamiento del cáncer en un paciente con aag baja

Info

Publication number
CR20150134A
CR20150134A CR20150134A CR20150134A CR20150134A CR 20150134 A CR20150134 A CR 20150134A CR 20150134 A CR20150134 A CR 20150134A CR 20150134 A CR20150134 A CR 20150134A CR 20150134 A CR20150134 A CR 20150134A
Authority
CR
Costa Rica
Prior art keywords
arry
cancer treatment
patient
aag
low
Prior art date
Application number
CR20150134A
Other languages
English (en)
Spanish (es)
Inventor
Karin Brown
Ronald B Franklin
Gary P Hingorani
Kevin S Litwiler
Brian J Tunquist
Duncan H Walker
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50101460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20150134A publication Critical patent/CR20150134A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4728Details alpha-Glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20150134A 2012-08-13 2015-03-13 Arry-520 para uso en el tratamiento del cáncer en un paciente con aag baja CR20150134A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261682682P 2012-08-13 2012-08-13
US201261734149P 2012-12-06 2012-12-06
US201361829779P 2013-05-31 2013-05-31
PCT/US2013/054807 WO2014028543A1 (en) 2012-08-13 2013-08-13 Arry-520 for use in treating cancer in a patient with low aag

Publications (1)

Publication Number Publication Date
CR20150134A true CR20150134A (es) 2015-05-06

Family

ID=50101460

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150134A CR20150134A (es) 2012-08-13 2015-03-13 Arry-520 para uso en el tratamiento del cáncer en un paciente con aag baja

Country Status (19)

Country Link
US (1) US20150231117A1 (h)
EP (1) EP2882436A1 (h)
JP (1) JP2015524845A (h)
KR (1) KR20150042280A (h)
CN (1) CN104869995A (h)
AU (1) AU2013302762A1 (h)
BR (1) BR112015003192A2 (h)
CA (1) CA2881937A1 (h)
CL (1) CL2015000348A1 (h)
CR (1) CR20150134A (h)
HK (1) HK1206275A1 (h)
IL (1) IL237227A0 (h)
IN (1) IN2015KN00676A (h)
MX (1) MX2015002018A (h)
NZ (1) NZ631362A (h)
PH (1) PH12015500306A1 (h)
RU (1) RU2617392C2 (h)
SG (1) SG11201501106TA (h)
WO (1) WO2014028543A1 (h)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2005113507A1 (en) * 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
SI2349259T1 (sl) * 2008-10-16 2016-03-31 Array Biopharma, Inc. Inhibitorji mitoze za povečanje apoptoze pri terapiji

Also Published As

Publication number Publication date
MX2015002018A (es) 2015-10-09
IL237227A0 (en) 2015-04-30
SG11201501106TA (en) 2015-06-29
RU2617392C2 (ru) 2017-04-24
EP2882436A1 (en) 2015-06-17
PH12015500306A1 (en) 2015-04-20
NZ631362A (en) 2016-09-30
KR20150042280A (ko) 2015-04-20
CL2015000348A1 (es) 2015-04-24
RU2015108740A (ru) 2016-09-27
BR112015003192A2 (pt) 2017-08-08
AU2013302762A1 (en) 2014-10-02
CA2881937A1 (en) 2014-02-20
CN104869995A (zh) 2015-08-26
IN2015KN00676A (h) 2015-07-17
HK1206275A1 (en) 2016-01-08
US20150231117A1 (en) 2015-08-20
WO2014028543A1 (en) 2014-02-20
JP2015524845A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
DOP2015000156A (es) Derivados de exendina-4 funcionalizada
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
PH12015500115A1 (en) Glucagon analogues
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
CO6811867A2 (es) Cannabinoides para uso en el tratamiento del dolor neuropático
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201400178A1 (ru) Лечение рака молочной железы
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
SV2012004192A (es) Nuevo uso antitumoral de cabazitaxel
CL2016000770A1 (es) Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX2015014344A (es) Terapia contra el cancer.
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
MX386144B (es) Inmunopotenciador.
MX2015007164A (es) Uso de estracto de fenogreco para mejorar la libido femenina.
MX2016002307A (es) Tratamiento para el cancer.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
ECSP11011550A (es) Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer